Truly control the high drug price and return the fake new drug to its original form

[China Pharmaceutical network industry trends] on January 25, the state new office held a briefing on Several Opinions on further reform and improvement of drug production, circulation and use policies (hereinafter referred to as "opinions") In the pharmaceutical industry, it has long been an "open secret" for some pharmaceutical companies and drugmakers to change the face of cheap and effective drugs and re submit them for approval as "new drugs" However, this opinion requires that the quality of drugs, especially the review and approval of new drugs, should be strictly controlled, which is of great significance to curb the spread of fake new drugs (really control the high drug price and return the fake new drug to the original image source: Baidu image) In the pharmaceutical industry, there are a variety of ways to change the face of drugs, some of which only change the packaging or name of drugs to increase the price without changing the composition and content of drugs; some of which change the dosage form and specification to increase the price of drugs without changing the pharmacological effect and clinical indications Some simply change their names for drugs Media have reported that roxithromycin has 40 names, ceftriaxone has 30 names, and the name of the antibacterial drug ofloxacin has reached as many as 52 As like as two peas, the common name of common cold medicine, such as fast, healthy, Tai Fu and Wing Lung, is compound paracetamol and amantadine hydrochloride capsules Colorful "more than one medicine" makes patients at a loss According to the data, more than 10000 new drugs are approved annually by the State Food and Drug Administration and the provinces (cities and districts) But the American drug regulatory agency only accepts more than 100 new drugs every year The number of new drugs in China is nearly 100 times that in the United States Is our drug R & D ability up to the world level? Or is the change of vest too frequent? The answer is self-evident The problem of "high drug price" and "more than one drug" has always been the focus of people's attention Relevant state departments have also taken some regulatory measures However, the illegal behaviors of drug companies, such as changing the name, specification and packaging of drugs and re pricing according to "new drugs", have not been stopped Some people in the drug retail industry have said frankly that in the past decade, the national development and Reform Commission has adjusted drug prices dozens of times, but after each "price limit order" was issued, 80% of the price limit drugs disappeared from hospitals and pharmacies It's true Once the national development and Reform Commission announces the price reduction of some drugs, hospitals and pharmacies will reduce or even stop the introduction of drugs Drug companies will reduce or stop the production of price reducing drugs, resulting in the disappearance of price reducing drugs from the market But the price is on the high side, and the "new drugs" with the same therapeutic effect are "developed" and quickly put on the market Chen Zhu, vice chairman of the National People's Congress and former Minister of health, took medical insurance reimbursement as an example when explaining the heavy medical expenses of residents Although the reimbursement proportion within the scope of basic medical insurance policy has reached 75%, the actual reimbursement ratio is only about 50% because the drugs outside the reimbursement catalogue have not been effectively controlled It's hard to imagine how many old medicines have been changed into medicines out of the medical insurance catalog
Therefore, since the State Council has put forward clear requirements for the review and approval of new drugs, relevant departments such as the development and Reform Commission, the health and Family Planning Commission, and the food and Drug Administration will upgrade their accounts to directors, improve regulatory measures, consider starting from the source of new drug registration, establish a new drug approval publicity system, and publicize the new drugs reported by pharmaceutical enterprises and those before formal registration in the media and on the Internet, so as to mobilize public participation in supervision We will be responsible for drug companies and distributors that produce and sell fake new drugs, and reward whistleblowers to keep all kinds of fake new drugs out of supervision In addition to strictly checking the examination and approval of new drugs, relevant departments should also thoroughly clean up all kinds of "new drugs" previously approved, and should not allow the "fake new drugs" to continue to fool the people From the perspective of drug pricing, drugs can be priced according to drug ingredients, not by drug name, to ensure the cost-effectiveness of drugs Cultivate a culture in which drug companies and drug dealers do not pursue the quantity of new drugs and pursue the safety and stability of drug names Only by taking multiple measures can we truly control the high drug prices and avoid the fake new drugs hollowing out the spirit of benefiting the people in the medical reform policy.